ARCA biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting | Plans Genetically-Targeted Development of AB171 for Peripheral Arterial Disease and Heart Failure